Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Patient Perception Study for AL-4943A

This study has been completed.
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: February 10, 2011
Last updated: December 14, 2012
Last verified: October 2011
To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Condition Intervention Phase
Allergic Conjunctivitis
Drug: AL-4943A
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Overall Patient satisfaction [ Time Frame: 7 days ] [ Designated as safety issue: No ]

Enrollment: 47
Study Start Date: September 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AL-4943A
One drop per day in both eyes
Drug: AL-4943A
Once daily topical ocular allergy medication used for 7 days


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of allergic conjunctivitis within last 24 months
  • Active signs and symptoms of ocular allergies

Exclusion Criteria:

  • Severe or serious ocular condition, ocular surgical intervention, ocular infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01294969

United States, Texas
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
  More Information

Responsible Party: Alcon Research Identifier: NCT01294969     History of Changes
Other Study ID Numbers: SMA-10-15 
Study First Received: February 10, 2011
Last Updated: December 14, 2012
Health Authority: Korea: Food and Drug Administration

Keywords provided by Alcon Research:
Allergic conjunctivitis

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Olopatadine Hydrochloride
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016